Similar to the way AGI's Mammostrat and Pulmostrat products were developed, AGI developed Pulmotype by translating insights from gene expression profiling of lung cancers into immunohistochemical assays for distinguishing cancer subtypes. Hundreds of novel antibodies were screened for their ability to classify NSCLC. A select few were identified in an initial discovery study using 300 lung cancer patients as useful for distinguishing histologic subtypes of lung cancer. The final optimal set of five antibodies were selected and a derived mathematical formula were combined to create the assay.

The Pulmotype assay is currently under further development and validation for clinical use.